📊 BBNX Key Takeaways
Investment Thesis
Beta Bionics demonstrates strong revenue growth of 53.9% YoY and an impressive 55.4% gross margin, indicating solid product-market demand and manufacturing efficiency. However, the company is deeply unprofitable with -73.0% net margin, burning significant cash (-$56.2M FCF annually), and lacks a clear path to profitability despite substantial assets. With only $31.6M in cash against annual cash burn of $50.9M from operations, the runway appears limited absent near-term operational improvements or capital infusion.
BBNX Strengths
- Robust revenue growth of 53.9% YoY indicating strong market demand and product traction
- Healthy gross margin of 55.4% demonstrates effective cost of goods control and pricing power
- Strong balance sheet with minimal debt (Debt/Equity 0.00x) and $287.6M in stockholders equity providing flexibility
- Excellent liquidity position with 8.66x current ratio provides near-term operational cushion
BBNX Risks
- Severe operating losses of -$71.7M with -71.5% operating margin indicate inability to scale profitably despite revenue growth
- Significant cash burn of -$56.2M in free cash flow annually; at current burn rate, $31.6M cash reserves provide ~7 months of runway
- Net income deteriorated to -$73.2M loss despite revenue growth, suggesting operating leverage is moving in wrong direction
- High insider trading activity (17 Form 4 filings in 90 days) may indicate uncertainty among management
Key Metrics to Watch
- Path to operating profitability - critical to monitor when operating margin approaches 0% or turns positive
- Cash burn rate and runway - essential to track quarterly operating cash flow to assess sustainability of current operations
- Operating leverage - watch gross profit growth relative to opex increases to identify when company reaches inflection point
- Operating margin trajectory - improvement toward industry benchmarks (>15-20%) would signal operational maturation
BBNX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.66x current ratio provides a solid financial cushion.
BBNX Profitability Ratios
BBNX vs Healthcare Sector
How Beta Bionics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BBNX Balance Sheet & Liquidity
BBNX 5-Year Financial Trend
5-Year Trend Summary: Beta Bionics, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.60 indicates the company is currently unprofitable.
BBNX Growth Metrics (YoY)
BBNX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.7M | -$9.7M | $-0.33 |
| Q2 2025 | $15.0M | -$14.5M | $-0.39 |
| Q1 2025 | $12.9M | -$12.4M | $-0.93 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BBNX Capital Allocation
BBNX SEC Filings
Access official SEC EDGAR filings for Beta Bionics, Inc. (CIK: 0001674632)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_070303.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_070301.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/form4-03062026_120301.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03032026_060310.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03032026_060308.xml | View → |
❓ Frequently Asked Questions about BBNX
What is the AI rating for BBNX?
Beta Bionics, Inc. (BBNX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBNX's key strengths?
Robust revenue growth of 53.9% YoY indicating strong market demand and product traction. Healthy gross margin of 55.4% demonstrates effective cost of goods control and pricing power.
What are the risks of investing in BBNX?
Severe operating losses of -$71.7M with -71.5% operating margin indicate inability to scale profitably despite revenue growth. Significant cash burn of -$56.2M in free cash flow annually; at current burn rate, $31.6M cash reserves provide ~7 months of runway.
What is BBNX's revenue and growth?
Beta Bionics, Inc. reported revenue of $100.3M.
Does BBNX pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
Where can I find BBNX SEC filings?
Official SEC filings for Beta Bionics, Inc. (CIK: 0001674632) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBNX's EPS?
Beta Bionics, Inc. has a diluted EPS of $-1.81.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.